This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Li, A. J. Articles by Karlan, B. Y. Search for Related Content PubMed PubMed Citation Articles by Li, A. J. Articles by Karlan, B. Y.

AIB1 Polymorphisms Predict Aggressive Ovarian Cancer Phenotype

Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Cedars-Sinai Medical Center, Geffen School of Medicine at UCLA, Los Angeles, California

Requests for reprints: Andrew J. Li, Department of Obstetrics and Gynecology, Cedars-Sinai Medical Center, 8700 Beverly Boulevard, Suite 160W, Los Angeles, CA 90048. Phone: 310-423-3599; Fax: 310-423-0155. E-mail: Andrew.Li{at}cshs.org

Purpose: The androgen receptor (AR) harbors a polymorphic CAG repeat sequence in exon 1, coding for a polyglutamine tract whose length inversely correlates with AR transactivation function. AIB1, an AR coactivator, expresses a similar polymorphic glutamine sequence within the carboxyl-terminal coding region. We hypothesized that genotypic variations in the androgen-signaling pathway promote aggressive epithelial ovarian cancer biology, and sought to examine the effect of AIB1 genotype on clinical outcome.

Experimental Design: Genotype analysis of the AIB1 CAG repeat region was done on 89 patients with epithelial ovarian cancer. Medical records were reviewed for clinicopathologic factors and survival. Data were examined using the ² test and Kaplan-Meier survival and Cox regression analyses.

Results: We identified four AIB1 genotypes, with glutamine codon lengths of 26, 28, 29, and 30. Patients with a short AIB1 genotype (with 28 CAG repeats) showed statistically shorter time to disease recurrence compared to those with a long genotype (29 CAG repeats; 15.0 versus 30.0 months; P = 0.01). Patients with short AIB1 also showed decreased overall survival (57.0 months) compared to those with a long genotype (median survival not yet reached; P = 0.02). When controlling for established prognostic factors, multivariate analysis identified the presence of a short AIB1 genotype as an independent poor prognostic factor for overall survival (P = 0.05).

Conclusions: These data suggest that short AIB1 genotypes may promote aggressive malignant phenotypes of epithelial ovarian cancer. (Cancer Epidemiol Biomarkers Prev 2005;14(12):2919–22)

This article has been cited by other articles:

				C. Dimple, S. S. Nair, R. Rajhans, P. R. Pitcheswara, J. Liu, S. Balasenthil, X.-F. Le, M. E. Burow, N. Auersperg, R. R. Tekmal, et al. Role of PELP1/MNAR Signaling in Ovarian Tumorigenesis Cancer Res., June 15, 2008; 68(12): 4902 - 4909. [Abstract] [Full Text] [PDF]

				H. Song, E. Hogdall, S. J. Ramus, R. A. DiCioccio, C. Hogdall, L. Quaye, V. McGuire, A. S. Whittemore, M. Shah, D. Greenberg, et al. Effects of Common Germ-Line Genetic Variation in Cell Cycle Genes on Ovarian Cancer Survival Clin. Cancer Res., February 15, 2008; 14(4): 1090 - 1095. [Abstract] [Full Text] [PDF]